11 February 2021 · Further commitment of £25.3 million in a £61.0 million expanded Series A; taking Syncona's total commitment to Quell to £59.3 million · First company globally targeting liver transplantation with engineered T regulatory cell therapy; set for clinical entry in the first half of 2022
· Research programmes initiated in Type 1 Diabetes ("T1D") and Amyotrophic Lateral Sclerosis ("ALS") Syncona Ltd ("Syncona") announces a £25.3 million new commitment in a £61.0 million expanded Series A financing for Quell Therapeutics ("Quell"). This is the largest amount of funding to date for any stand-alone engineered T regulatory cell (Treg) company and this new commitment takes Syncona's total commitment to this business to £59.3 million. Syncona has invested £35.1 million of its total commitment and values its investment at that amount (equivalent to cost). Syncona will have a 74 per cent fully diluted ownership stake in Quell at the point current commitments are invested.